The Efficacy of Venlafaxine in Treatment of Depression in Parkinson's Disease


Torun F., Bayulkem K., Torun S. D.

KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, vol.21, no.1, pp.18-23, 2011 (Journal Indexed in SCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 21 Issue: 1
  • Publication Date: 2011
  • Title of Journal : KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY
  • Page Numbers: pp.18-23

Abstract

Objective: Depression is the most common psychiatric disorder appearing in Parkinson's Disease (PD) with an average prevalence rate almost 40-50 %. Selective serotonin and norepinephrine reuptake inhibitors (SNRIs) are currently used in the treatment of depression in patients with PD, but we have not found any studies in the literature regarding this treatment choice. The aim of this prospective study was to investigate the therapeutic efficacy of venlafaxine, which is a SNRI antidepressant, in the treatment of depression in Parkinson's disease.